Investment analysts at Wells Fargo & Co began coverage on shares of Endocyte (NASDAQ:ECYT) in a report released on Friday, Marketbeat.com reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the stock. ValuEngine lowered shares of Endocyte from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. BidaskClub raised shares of Endocyte from a “sell” rating to a “hold” rating in a report on Saturday, March 3rd. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Finally, Cowen raised shares of Endocyte from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $7.00.
Endocyte (NASDAQ ECYT) opened at $10.82 on Friday. The stock has a market cap of $426.93, a P/E ratio of -8.45 and a beta of 1.02. Endocyte has a 1-year low of $1.17 and a 1-year high of $11.54.
In other Endocyte news, insider Philip S. Low sold 50,511 shares of Endocyte stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.41, for a total value of $222,753.51. Following the transaction, the insider now directly owns 354,050 shares of the company’s stock, valued at $1,561,360.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Christopher P. Leamon sold 5,036 shares of Endocyte stock in a transaction on Friday, March 9th. The stock was sold at an average price of $9.07, for a total transaction of $45,676.52. Following the completion of the transaction, the vice president now directly owns 143,470 shares in the company, valued at $1,301,272.90. The disclosure for this sale can be found here. Insiders sold 106,058 shares of company stock worth $491,184 over the last ninety days. Corporate insiders own 14.86% of the company’s stock.
Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its stake in shares of Endocyte by 1,064.3% during the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 393,975 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Endocyte during the fourth quarter worth $6,213,000. EAM Investors LLC acquired a new stake in shares of Endocyte during the fourth quarter worth $420,000. Dimensional Fund Advisors LP lifted its stake in shares of Endocyte by 34.1% during the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Endocyte by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,580 shares of the biopharmaceutical company’s stock worth $1,257,000 after buying an additional 86,800 shares during the period. Institutional investors and hedge funds own 41.56% of the company’s stock.
WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/03/09/endocyte-ecyt-now-covered-by-wells-fargo-co.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.